EXOZYMES INC. Derivative Liability, Securities Sold under Agreements to Repurchase, Securities Loaned
EXOZYMES INC. (EXOZ) had Derivative Liability, Securities Sold under Agreements to Repurchase, Securities Loaned of $800.00 thousand as of 2024-09-30, per its 10-Q filed 2024-11-12.
Financial Statements › Notes
us-gaap:DerivativeLiabilitySecuritiesSoldUnderAgreementsToResellSecuritiesLoaned · last filed 2024-11-12
- 2024-09-30: Derivative Liability, Securities Sold under Agreements to Repurchase, Securities Loaned $800.00K.
| Period end | Derivative Liability, Securities Sold under Agreements to Repurchase, Securities Loaned |
|---|---|
| 2024-09-30 | $800.00K 10-Q · filed 2024-11-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BioAtla, Inc. (BCAB) | United States | $0.058B | -0.21 |
| ImageneBio, Inc. (IMA) | United States | $0.056B | -1.31 |
| Inmune Bio, Inc. (INMB) | United States | $0.056B | -2.48 |
| MiNK Therapeutics, Inc. (INKT) | United States | $0.063B | -5.37 |
| Eloxx Pharmaceuticals, Inc. (ELOX) | United States | $0.065B | |
| Tevogen Inc. (TVGN) | United States | $0.049B | |
| Instil Bio, Inc. (TIL) | United States | $0.048B | -1.73 |
| BioStem Technologies, Inc. (BSEM) | United States | $0.069B | |
| LeonaBio, Inc. (LONA) | United States | $0.047B | -0.61 |
| CHAMPIONS ONCOLOGY, INC. (CSBR) | United States | $0.070B | -68.02 |